Richter transformation (RT) is a rare but serious complication of chronic lymphocytic leukemia (CLL), where the disease transforms into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). According to verified medical sources, RT occurs in approximately 2-10% of CLL patients during their disease course. The transformation is associated with a poor prognosis, with median survival often less than one year after diagnosis.
Risk factors for RT include advanced Rai stage at CLL diagnosis, unmutated IGHV status, and certain genetic abnormalities such as TP53 disruption or MYC activation. The diagnosis is confirmed by lymph node biopsy showing large B-cell lymphoma cells, often with a clonal relationship to the underlying CLL clone.
Treatment options for RT are limited and depend on the patient's fitness and prior therapies. For fit patients, chemoimmunotherapy regimens like R-CHOP or R-EPOCH may be used, but outcomes remain poor. Novel agents such as PD-1 inhibitors (e.g., pembrolizumab) and bispecific antibodies are under investigation in clinical trials.
Prognosis remains guarded, with clinical trials exploring targeted therapies and cellular immunotherapies. Early detection through surveillance imaging and biopsy of rapidly enlarging lymph nodes is critical for timely intervention.
